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Abstract
Brugia malayi is one of three species of nematode known to cause lymphatic filariasis
(LF) in humans. LF infects over 120 million people, causing debilitating disease. Various global
programs have been launched in the past 20 years to eliminate LF. These programs have greatly
scaled up the resources and efforts allocated to halting the transmission and reducing disease
burden. Only a few drugs are used to treat LF, and resistance is thus a devastating possibility.
Research aimed at identifying new drug targets could therefore prove essential in elimination of
LF.
Genetic manipulation of B. malayi has been limited to transient transfections. A
transfection system allowing for stable integration of transgenic sequences into the nuclear
genome of this parasite would enable more robust studies that could lead to identification of
novel drug targets and vaccine candidates. The piggyBac (pB) transposon system has been
successfully applied to develop a stable transfection system in a variety of species. This system
involves two plasmids, a helper and a donor. The donor plasmid contains the target DNA and a
selectable marker flanked by specific inverted terminal repeat (ITR) regions. The helper plasmid
expresses the pB transposase that will catalyze the precise integration of any DNA report tools
necessary to adapt the pB system in B. malayi. Three versions of the donor plasmid were
constructed, each containing a Gaussia Luciferase (GLuc) selectable marker but differing only
by the fluorescent protein expressed. The construct containing a YFP gene was used to transfect
embryos via biolistics to test whether YFP and GLuc are expressed
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Chapter One: Introduction
Lymphatic filariasis – the disease and its control
Filarial parasitic nematodes threaten hundreds of millions of people worldwide, mostly in
developing areas. Lymphatic filariasis (LF), caused by Wuchereria bancrofti and two Brugia
species, is a neglected tropical disease that commonly leads to elephantiasis, hydrocele, and
lymphedema (WHO, 2017).
Filarial parasites have a complex life cycle, involving stages in both a mosquito vector
and mammalian host. The infectious third-stage filarial larvae (L3) are injected into a person by
an infected mosquito during a blood meal. These larvae develop into adults that reside in the
lymphatics, most commonly in the extremities and male genitalia. The adults will produce an
average of 10 thousand microfilariae a day that migrate from the lymph to the blood channels
where they can be ingested by a mosquito, facilitated by a periodicity that causes peak
concentrations to coincide with the local feeding habits of the mosquito vector. Once inside a
mosquito, the microfilariae molt twice to become L3 larvae and can infect another person (CDC
DPDx, 2016; Taylor et al., 2010).
In the year 2000, over 120 million people worldwide were infected with lymphatic
filariasis (LF) and approximately 1 billion people in 54 countries were at risk (WHO, 2017). This
led to the launch of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) by the
WHO in 2000. The GPELF, visualized in Figure 1, utilizes a multimodal approach consisting of
mass drug administration (MDA), vector control and integrated vector management (VC/IVM),
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and Morbidity management and disability prevention in populations with LF (MMDP) (Ichimori
et al., 2014).

Figure 1: Global strategy to eliminate lymphatic filariasis (Ichimori et al., 2014)
Open access source: http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003328
Since the launch of GPELF, the London declaration was signed in 2012 and committed to
eliminating LF by 2020, the Bill & Melinda Gates Foundation called for eradication by 2030,
and the UN General assembly specifically targeted all neglected tropical diseases (NTDs) for
elimination by 2030 (Rebollo & Bockarie, 2016). All of these initiatives have dramatically
scaled up the resources and efforts to reduce the incidence and burden of LF.
Between 2000 and 2012, the MDA program resulted in 4.45 billion treatments being
consumed by people living in endemic areas, leading to an estimated 96.7 million (Ramaiah &
Ottesen, 2014). Seven billion treatments have been consumed as of today. The economic benefit
of GPELF, in terms of amount saved over the lifetimes of the benefit cohorts, has been estimated
to be between US$69.30–150.7 billion (Turner et al., 2016).
There are four main classes of drugs used to treat filarial diseases: diethylcarbamazine
(DEC), benzimidazoles (notably, albendazole), avermectins, and oxytetracyclines (which affect
2

the Wolbachia endosymbiont); the first three affect the primarily the microfilariae in the blood
(Scott & Ghedin, 2009). The current recommendation by the WHO is annual DEC and
albendazole, though research has shown that including ivermectin (a derivative of avermectin)
may improve microfilariae clearance (Ismail et al., 2001). The WHO also recommends
preventive chemotherapy and transmission control (PCT) as the first-line strategy to achieve
transmission interruption.
MDA will lead to stronger selective pressure on these parasites, potentially leading to the
emergence of drug-resistant strains. New treatments could provide essential to eliminating LF,
should substantial resistance arise.

Genetic manipulation of Brugia malayi
The filarial genome project was launched in 1994, with the goal of developing a
framework to study the genome of human filarial parasites. Brugia malayi was selected as the
organism of choice for this project, as it was the only filarial parasite readily maintained in small
laboratory animals (Unnasch, 1994).
In following few years, over 22,000 expressed sequence tags (ESTs), short fragments of
cDNA used to identify genes, had been produced from B. malayi and deposited in the public
databases by laboratories from all over the world (Blaxter et al., 2002). While these studies were
useful for gene discovery, new methods were needed to study gene function and regulation for B.
malayi.
Reverse genetic approaches have been successfully used to study the free-living
nematode Caenorhabditis elegans. Transient transfection by microinjection and particle
bombardment (biolistics) were successfully used to introduce exogenous DNA into C. elegans,
and later in B. malayi (Higazi et al., 2002). In a biolistic transfection, concentrated DNA is
3

precipitated onto small gold particles and propelled into embryos under high pressure; this
method has been employed to study gene regulation in B. malayi (Shu et al., 2003; Higazi and
Unnasch, 2004; Higazi et al., 2005; de Oliveira et al., 2008; Liu et al., 2010). Transient
transfections are particularly limiting for studying parasites with complex life cycles, as the
exogenous DNA introduced is not inherited. In a biolistic transfection, the transfected embryos
are rendered developmentally incompetent. The genome of B. malayi was sequenced and
compared to that of C. elegans, providing a foundation for future genetic studies (Ghedin et al.,
2007).
Xu et al. (2011) demonstrated a novel method of transfecting developmentally competent
B. malayi larvae, using a method of chemical transfection in cell culture while inducing the
molting of L3 larvae to increase parasite permibility. Reporter activity was detected from adults
and microfilariae retrieved from jirds (mammalian host used to maintain B. malayi). While this
study demonstrated a method of transfecting the parasites without rendering them
developmentally incompetent, the transgenic sequences introduced were probably not inherited
in a Mendelian fashion. A stable method of transfection allowing the integration of transgenic
DNA into the nuclear genome of B. malayi would enable more robust genetic studies
The piggyBac (pB) transposon system has been applied to a wide variety of invertebrates
and vertebrates (Lok, 2013). Of particular relevance, the pB system was utilized to integrate
transgenes into the genome of the parasitic nematode Strongyloides ratti (Shao et al., 2012).
Large inserts (up to 14 kb) have been delivered without a significant loss in efficiency (Vargas et
al., 2016)
The pB transposon system utilizes two plasmids to enable stable insertional mutagenesis:
a donor and a helper. The donor plasmid contains the DNA targeted for integration, flanked by
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the inverted terminal repeats (ITR) region. The helper plasmid expresses the pB transposase,
which catalyzes that integration of DNA flanked by ITRs into the TTAA sites of the
chromosomes (Balu & Adams, 2006). Adapting the methods from Xu et al. (2011) to introduce
the proper donor and helper plasmids could lead to the development of a stable transfection
system using the pB system.
Objective
The goal of this project was to design a donor plasmid that could be used in a piggyBac
transfection system. A plasmid designed for piggyBac transfection with a secreted Gaussia
luciferase (GLuc) selectable marker flanked by ITRs, with its expression driven by the HSP70
promoter and its 3’UTR was the starting point for this process. While GLuc is a sensitive
reporter assay that can confirm a successful transfection, it does not allow for positive selection
of transfected parasites or a direct inspection to observe localization. For this reason, we planned
to use a fluorescent protein as a reporter assay. Due to reported autofluorescence, three different
fluorescent proteins were chosen: GFP, YFP, and CherryRed (Table 1); all were purchased from
addgene (Cambridge, MA).
Table 1. Fluorescent proteins chosen.
Name
Ex
Em
GFP
488
507
YFP
516
529
CherryRed
587
610

Backbone plasmid
pCS2+8NeGFP
pCS2+8NmCitrine
pCS2+8NmCherry

Expression spp.
C. elegans
C. elegans
C. elegans

The BmRPS12 promoter, which drives the expression of the 12 kDa small subunit
ribosomal protein gene (de Oliveira et al., 2008), was picked to drive the expression of the
fluorescent proteins. This promoter, like the HSP70 promoter, has been mapped in detail. The
donor plasmid was then transfected into embryos by biolistic transfection to test the expression
efficacy.
5

Chapter Two: Materials & Methods
General Methods
Polymerase chain reaction (PCR)
PCR was used to produce large quantities of the desired inserts and to confirm that an
insert was present.

Restriction enzyme (RE) digest
Restriction enzymes (REs) are endonucleases that recognize specific nucleotide
sequences and cleave the DNA in a predictable manner. In order to engineer an insert into a
vector, restriction enzymes are used to linearize the insert and vector, and produce
complementary nucleotide overhangs. These complementary overhangs will allow the insert and
vector to be annealed together via hydrogen bonding. As will be discussed later, DNA ligase can
then join the adjacent strands in a ligation reaction.

DNA extraction
Following RE digest, DNA was extracted from solutions using either a phenolchloroform extraction or an agarose gel extaction. For a phenol-chloroform extraction, an equal
volume of phenol:chloroform is added to a DNA sample. The phenol:chloroform denatures the
proteins (i.e. RE enzymes), which are then separated from DNA by centrifugation. The DNA is
then purified by an ethanol precipitation, which involves precipitating DNA out of a solution by

6

concentrated salt and cold temperature. Once precipitated, the DNA can be pelleted by
centrifugation and further washed by 70% ethanol. The DNA is then dissolved in 1X TE.
An agarose gel extraction is used to separate and purify two strands of DNA. This
method is used when an insert is amplified from plasmid DNA and to remove an insert from an
undesired vector. The sample is run on an agarose gel, which separates linear strands of DNA by
size, and extracted using the Wizard® SV Gel and PCR Clean-Up System kit (Promega).

Heat-shock transformation
A heat-shock reaction allows the introduction a plasmid into engineered E. coli cells to
produce large, stable quantities of the plasmid or confirm that a ligation reaction was successful.
The protocol varies according to cells used.

PCR screen
Following a transformation, up to 40 colonies can be screened for presence of a plasmid
containing the desired insert. Colonies are picked an grown overnight in LB containing 100
ng/µL of ampicillin. Following incubation, 100µL of solution is transferred to 1.7 mL eppendorf
tube and boiled at 100ºC for 10 minutes on a heating block, and subsequently centrifuged for 5
minutes; this method allows for quick production of a DNA-containing solution that can be used
as a template in a PCR.
Two different types of PCR screens can be run: directional or non-directional, differing
only by primers used in reaction. A non-directional PCR screen uses a forward and reverse
primer flanking the multiple cloning site, while a directional PCR will use a flanking primer and
an insert-specific primer, each of opposite directions.
PCR samples are run on an agarose gel to confirm the presence of an insert.
7

High quality plasmid miniprep
The plasmid from a liquid bacterial suspension of less than 5 ml is isolated and purified
using the QIAprep Spin Miniprep Kit (Qiagen).

Sequencing
The plasmid from a liquid bacterial suspension of less than 5 ml is isolated and purified
using the QIAprep Spin Miniprep Kit (Qiagen). The purified plasmids are then sent to Eurofins
Genomics for sequencing, according to their instructions. Analysis of the sequencing results is
conducted via BLAST search (NIH NCBI BLASTn).

Preparation of bacterial glycerol stock
Bacterial cultures containing a desired plasmid will be stored with 25% glycerol at -80ºC
for long-term storage. This stock is prepared by mixing 500µL of 50% glycerol with 500µL of
bacterial solution in a cryopreservation vial.

Inserting Multiple Cloning Site (MCS)
Designing and preparing MCS insert for cloning
The sequence of the parental donor plasmid was analyzed to find all non cutters, or
restriction enzymes whose recognition site was absent in the plasmid. Eight non-cutters were
chosen, one of which (BclI) was chosen for the MCS to be cloned into. The rest were arranged to
allow maximal overlap, shortening the total length (Table 2).

Table 2. Full MCS designed. Overlapping regions are underlined.
BclI
NdeI
AatII
SmaI
ClaI
MluI

BglII

BclI

TGATCA

AGATCT

TGATCA

CATATG

GACGTC

CCCGGG

ATCGAT

ACGCGT
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Two oligonucleotides, containing the full MCS, were designed to form 4 base-pair 5’
overhangs when annealed (Fig. 2). Approximately 5 µM of these individual oligonucleotides
were phosphorylated with 10 units of T4 polynucleotide kinase (NEB) in a solution containing 1
mM of ATP and incubated at 37ºC for 30 minutes. After inactivating the kinase, the
phosphorylated oligonucleotides were annealed in a thermocycler by heating to 100ºC for 3
minutes and subsequently cooling to 25ºC at a rate of -1ºC every 30s.
1. Primers designed and ordered
Fwd: 5’ GATCATATGACGTCCCGGGATCGATACGCGTAGATCT 3’
Rev: 5’ GATCAGATCTACGCGTATCGATCCCGGGACGTCATAT 3’
2. Oligonucleotides individually phosphorylated
3. Annealed to leave 4bp overhangs:
5’ GATCATATGACGTCCCGGGATCGATACGCGTAGATCT 3’
3’
TATACTGCAGGGCCCTAGCTATGCGCATCTAGACTAG 5’
Figure 2. Generating MCS insert
Preparing the vector for insertion of MCS
Site-directed mutagenesis was used to introduce a BclI site downstream of the HSP70 3’
UTR and upstream of the ITR2 site. Two overlapping 40bp primers with a central mutation site
were designed to introduce a 2bp change in the sequence (Fig. 3). The reagents and protocol
were provided by the GENEART® Site-Directed Mutagenesis System kit (ThermoFisher, USA).
Original: 5’ ACGCGGTCGTTATAGTTCAAAATCAGTGACACTTACCGCA 3’
Mutg_Fwd: 5’ ACGCGGTCGTTATAGTTCATGATCAGTGACACTTACCGCA 3’
Mutg_Rev: 5’ TGCGGTAAGTGTCACTGATCATGAACTATAACGACCGCGT 3’

Figure 3. Mutagenesis primers.
Red represents the mutated base-pairs
The linearized vector was then transformed into DH5ɑ-T1 cells provided by the
manufacturer. Six colonies were picked, grown overnight in LB media containing 100 ng/µL of
ampicillin, purified, and sent for sequencing to confirm presence of desired mutation and
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absence of undesired mutations. Once confirmed, 5µg of the vector was digested with BclI and
dephosphorylated with 5 units of calf intestinal alkaline phosphatase. The vector was then
extracted via phenol/chloroform extraction and purified by ethanol precipitation.

MCS ligation
The MCS insert was ligated into the vector at a 3:1 molar ratio by incubating at 16ºC for
16 hours. The mixture, listed in (Table 3), was assembled in an RNase-free, thin-walled tube
along with 1X ligation buffer. Two control reactions were run: one with no insert, to determine
how much self-ligation is present, and one with no insert and no T4 ligase, to determine how
much uncut vector is in the plasmid.
Table 3. MCS ligation components
Ligation (µL) Control 1 (µL) Control 2 (µL)
H2O

26.3

29.3

27.3

10X Ligase buffer 3.5

3.5

3.5

Vector

2.2

2.2

2.2

Insert

1.0

0.0

0.0

T4 Ligase

2.0

0.0

2.0

TOTAL

35.0

35.0

35.0

Confirmation of Ligation
A PCR screen was run on selected colonies against a control to analyze relative size
difference. Positive hits were sent for sequencing, one colony was stored in 25% glycerol at
-80ºC.
10

Cloning methods for fluorescent protein constructs

Figure 4. General overview of construct designs.
Six different ligations were conducted to generate 5 different constructs
Primer design and PCR amplification
The primers used in this study are provided in Table 4. The primers for the RPS12
promoter were designed with synthetic Nde1 sites, while its 3’ UTR was amplified with a
11

synthetic BglII site to be cloned into the corresponding site. All the primers for the fluorescent
proteins were designed for the fluorescent protein genes to be cloned into the MluI site of the
MCS. The sequences of CherryRed and YFP had identical 5’ and 3’ 30 bp sequences, allowing
them to be amplified using the same primers. All fluorescent proteins were amplified from the
fluorescent protein backbones purchased from Addgene (Cambridge, MA).
Insert DNA was amplified via PCR according to the components and program in Table 5
and Table 6.

Table 4. Primers used for sequencing and amplification of inserts
Name

Sequence

pB-Screen_Fwd
pB-Screen_Rev
RPS12-Pro_Fwd
RPS12-Pro_Rev
RPS12-3UTR_Fwd
RPS12-3UTR_Rev
Cherry/YFP_Fwd
Cherry/YFP_Rev
GFP_Fwd
GFP_Rev

5’
5’
5’
5’
5’
5’
5’
5’
5’
5’

CGTATGAGTTAAATCTTAAAAGTCACG 3’
GTGCATTTAGGACATCTCAGTC 3’
GGGCATATGGCTTAAGGAGAATTTTTAAAAAACTATAGAG 3’
GGGCATATGCATGTTCAGCAGTTGTCCTCGAT 3’
GGGAGATCTTGACTATTGTTTGTTTATTGTTTGTATTGAAG 3’
GGGAGATCTGCCCAAGCAATTTCGAATGA 3’
GGGACGCGTGTGCATTTAGGACATCTCAGTC 3’
GGGACGCGTCTTGTACAGCTCGTCCATGC 3’
GGGACGCGTCGGAGCAAGCTTGATTTAGG 3’
GGGACGCGTTGGTTTGTCCAAACTCATCAA 3’
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Table 5. PCR components for insert amplification
Components (Starting Concentration)

Volume (µL)

DNase-free water

27.5

10X PCR buffer

5.0

MgCl2 (50mM)

4.0

dNTPs (2 mM)

10.0

Forward Primer (50 µM)

0.5

Reverse Primer (50 µM)

0.5

Taq DNA polymerase (5 U/µL)

0.5

DNA template

2.0

TOTAL

50

Table 6. PCR thermocycler program for insert amplification
Temperature (ºC) Duration

# of Cycles

Denaturation

94ºC

3 min

1

Amplification

94ºC
(Tm-5)ºC
68ºC

30 sec
40 sec
1.5 min

30

20 min

1

Final extension 68ºC
4ºC

Until storage 1

Strata ligation
All of the inserts were amplified to be cloned into the linear StrataClone PCR cloning
vector. This vector contains topoisomerase-charged ends with modified uridine overhangs (that
binds to 3’ adenosine overhangs of PCR products) and a loxP recognition sequence that enables
recombination to create a circular DNA molecule containing the PCR product
13

The PCR product and vector were incubated for 5 minutes at room temperature and
subsequently transformed into Cre recombinase-expressing cells provided by manufacturer. Cre
recombinase catalyzes the recombination between the two loxP sites, resulting in a circular
plasmid containing the PCR product. The vector contains a lacZ´ α-complementation cassette,
which enables blue-white screening. Up to 40 white colonies are grown in liquid media and
screened by PCR for presence of insert.

Preparation of insert and vector
Two separate colonies containing the proper vector and the proper insert in a strata vector
were purified using the QIAGEN Plasmid Midiprep kit. Once purified, 10µg of insert and 5µg
of vector were separately digested by the same restriction enzyme (to produce complementary
overhangs). The insert was extracted via agarose gel extraction to separate it from the Strata
vector and the vector was purified via phenol/chloroform extraction, followed by an ethanol
precipitation.

Ligation of insert into vector
Two different protocols were used for ligations. The first protocol was used to ligate the
RPS12 promoter & its 3’ UTR, as well as YFP into the final vector. The second protocol was
used to ligate CherryRed and GFP into the vector. In the first protocol, the insert to vector molar
ratio was 3 to 1. The components added were according to Table 7. The solutions were incubated
at 16ºC for 16 hours and the T4 ligase was inactivated at 65ºC for 10 minutes (Table 7).
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Table 7. Ligation 1 components
Ligation (µL) Control 1 (µL)
H2O

To 35µL

To 35µL

10X Ligase buffer 3.5

3.5

Insert:Vector

3:1

No insert

T4 Ligase

1.0

1.0

TOTAL

35.0

35.0

This protocol did not yield any success for the ligations of CherryRed and GFP; it was
therefore modified in the hopes of increasing ligation efficiency. The insert:vector ratio was
increased to 6:1 and the total volume was reduced to 20 µL. The insert and vector were heated at
65ºC for 5 minutes prior to adding ligase buffer and ligase to disrupt an insert-to-insert or vectorto-vector sticky end interactions. The 16ºC incubation was shortened to 15 hrs and preceded by
30 minutes at 4ºC, while followed by 30 minutes at 22ºC (Table 8).
Table 8. Ligation 2 thermocycler program
Temperature (ºC) Duration
4ºC

30 min

16ºC

15 hrs

22ºC

30 min

65ºC

10

4ºC

Infinite

Following ligation, 3µL of the ligation solution was transformed into Subcloning
Efficiency™ DH5α™ Competent Cells (ThermoFisher) according to the manufacturer’s
protocol. Up to 40 colonies were picked and screened by PCR for the presence of insert in the
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proper orientation. Up to 3 positive hits were sent for sequencing and one confirmed colony was
stored in glycerol at -80ºC.

Biolistic transfection
Approximately 30 mg of gold beads (0.6µm diameter) were washed with 1ml of 70%
ethanol once folowed by three washes with 1ml nuclease free water. The beads were then
resuspended in 500µL of 50% glycerol, giving a concentration of 60 mg/ml, and stored at 4ºC.
The beads were resuspended in the solution by placing on a platform vortex for 15 minutes; 50
µL of this solution are transferred to another centrifuge tube for use in a single transfection.
The new tube was placed on the platform vortex while the remaining components were
added in order: 10µL of 2µg/µL purified DNA in water, 55µL of 2.5 M CaCl2, and 22µL of 0.1
M of spermidine. After the sample was vortexed for 3 more minutes and allowed to settle, the
beads were washed once with 280µL of 75% ethanol and once with 280µL of absolute ethanol.
The beads were then resuspended in 18µL of absolute ethanol, with 6µL loaded onto
macrocarriers.
The embryos are isolated by dissection of adult female worms. Five female worms were
used per transfection. The adult worms are visible with the naked eye and can be easily isolated
on a 3.5 cm petri dish in a flow hood. The worms were vigorously diced using a curved bladed
scalpel to release the embryos. Embryos were collected into a 1.7 mL tube in around 500µL of
CF-RPMI. The embryos were then centrifuged at 6000 x g and resuspended in 30µL of CFRPMI. These embryos are then spread in the center of a 3.5 cm petri dish
The DNA/bead-coated macrocarrier, the embryo-containing dish, and an 1100 PSI break
disk were all properly loaded onto a biolistic unit (BioRad, Hercules, CA). The embryos were
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then bombarded with the beads at 1100 PSI under a vacuum of 12.5 in of mercury. The embryocontaining dish was then placed in a humid box and covered for 5 minutes. Following
incubation, 1.6 ml of CF-RPMI was added to the dish and placed in a 37ºC (5% CO2) incubator
for 48 hours.

Analysis of Transfected Embryos
Secreted luciferase assay
Following the 48-hour incubation, 50µL of BioLux GLuc substrate was mixed with 5ml
of BioLux GLuc Assay buffer in a glass culture tube. One blank was run to assess background
along with 20µL of each sample mixed with 50µL of the GLuc assay solution. The luciferase
activity was measured using an FB12 Tube Luminometer (Berthold). The activity is measured in
relative light units (RLU).

Fluorescence microscopy assay
Following incubation, 20µL of embryos in CF-RPMI were pipetted onto a microscope
slide and fixed with coverslip. Various slides were observed under varying emission wavelengths
using an automated fluorescence microscope (Zeiss).
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Chapter Three: Results
The site-specific mutagenesis, with the goal of generating a 2-bp mutation to create a
BclI site was confirmed by sequencing (Fig. 5). This BclI site allowed for the insertion of a
multiple cloning site, which in turn enabled fluorescent proteins to be cloned in with the
BmRPS12 promoter and its 3’ UTR to drive the expression. The plasmid with only the MCS was
named pBACII-BmGluc (Fig. 6); this plasmid was transfected via biolistics and analyzed via
luciferase assay (Fig. 12).

Figure 5. Sequencing result of mutagenesis.
Highlighted region is BclI site.

Figure 6. Sequencing result of MCS ligation.
Highlighted region are BclI sites flanking the MCS.
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Prior to being cloned into the MCS, all individual inserts were cloned into the Strata
vector as described in the methods section and confirmed by sequencing
The first insert to be ligated into the MCS was the RPS12 3’UTR. This insert was
amplified from the genomic DNA of B. malayi. A directional PCR screen was run on 38
colonies, with two positive clones detected; both of these were confirmed by sequencing.

Figure 7. PCR screen for RPS12 3’ UTR ligation
Next, the RPS12 promoter was ligated into the MCS. Only one colony grew from the
ligation reaction, and it was confirmed by PCR screen to have the insert in the correct orientation
(Fig. 8). The plasmid containing the RPS12 promoter and its 3’UTR was named pBACIIBmGluc-RPS12 and stored at -80ºC; this plasmid was used as a control for a fluorescence
microscopy assay and a luciferase assay (Fig. 13)
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Figure 8. PCR screen for RPS12 promoter ligation
From left to right: Directional PCR screen, insert-specific screen, flanking screen
All of the fluorescent protein inserts were individually ligated into the MluI site, flanked
by the RPS12 promoter and its 3’ UTR. A directional PCR screen was run for all the individual
ligations with varying levels of success: the YFP ligation had 12 positive hits out 18 (Fig. 9); the
GFP ligation had 6 out of 16 (Fig. 10); and the cherryRed had 1 out of 13 (Fig. 11). Only the
construct containing YFP was transfected via biolistics into B. malayi embryos and analyzed by
luciferase assay (Fig. 13) and fluorescence microscopy assay.
The pBACII-BmGluc-YFP construct was analyzed by fluorescence micropsy using the
pBACII-BmGluc-RPS12 as a control; both of these constructs were identical with the exception
of the YFP gene. Autofluorescence was observed equally in both samples, with no significantly
greater fluorescence in the YFP channel.
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Figure 9. Direction PCR screen for YFP ligation
Expected size: 1919 bp

Figure 10. Directional PCR screen for GFP ligation
Expected size: 2128 bp

Figure 11. Directional PCR screen for CherryRed ligation
Expected size: 1910 bp
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Figure 12. pBACII-BmGluc Luciferase assay.
The two samples of embryos were transfected via biolistics with pBACII-BmGluc
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Figure 13. pBACII-BmGluc-YFP Luciferase assay.
pBACII-BmGluc-RPS12 served as a control. Both samples transfected via biolistics
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Chapter Four: Discussion
The luciferase assays for the three different constructs demonstrate that they were all
successfully transfected into the embryos. The inconclusive results from the fluorescent
microscopy assay could be due to a number of reasons. One reason may be that the RPS12
promoter and its 3’UTR did not successfully drive the expression of the YFP. Expression of the
YFP might have also been at a very low level, rendering it difficult to discern between
autofluorescence and YFP-derived fluorescence. No autofluorescence was detected in
undisturbed microfilariae and L3s. It is possible that the stress induced to prepare the embryos
for transfection resulted in high levels of autofluorescence. Studies in the lab are currently
ongoing to test a modified version of the in vitro transfection described in Xu et al. (2011) that
uses a lipofection instead of a calcium phosphate precipitate-mediated transfection. This
transfection, conducted on the more robust L3s, does not require much stress to be induced and
could provide a method to detect fluorescence without the impeding autofluorescence. If no
significant fluorescence is detected, a different promoter could be used or introns specific for
BmRPS12 could be cloned in to increase the efficiency of expression.
These constructs could be used for spatial and temporal analysis of gene expression,
which could elucidate gene function. In an organism with a complex life cycle like B. malayi,
different genes will be expressed at various times throughout the life cycle. Fluorescent protein
reporters allow researchers to monitor the gene expression in a specific cell or tissue and at
certain times in a life cycle. Hunt-Newbury et al. (2007) used a GFP construct to generate spatial
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and temporal tissue expression profiles for 10% of all genes in C. elegans, analyzing each stage
of development.
MicroRNAs (miRNAs) play an important role in regulating posttranscriptional gene
expression. These small RNA molecules generally form a protein complex that binds to
sequences in the 3’UTR of mRNAs, and could be targeted for the development of novel
treatments (Poole et al., 2014). Different miRNAs are restricted to different life cycle stages in
nematodes, suggesting a potential role in their development.
miRNA activity has been analyzed using GLuc as a reporter, demonstrating that miR-71
decreased reporter activity when inserted into the 3’UTR (Liu et al., 2015). Using GLuc as a
reporter, however, does not all for monitoring miRNA according to different tissue types. Using
a GFP as a reporter, Brown et al. (2006) were able to demonstrate that miR-142 was suppressed
only in hematopoietic lineages. This result showed that GFP was an effective reporter to analyze
how miRNAs could efficiently differentiate gene expression among different tissue types.
Kato et al. (2009) developed a vector system encoding two different fluorescent proteins
(GFP & RFP). The GFP was connected to a specific miRNA (miR-133), while the RFP was not.
The researchers demonstrated in real-time the reduction of the GFP with no effect on RFP. This
study demonstrates how different fluorescent protein constructs could be utilized in tandem to
more efficiently study gene regulation in varying tissue and cell types.
Future tools for genetic studies of Brugia malayi could be adapted from studies of other
nematodes, especially C. elegans. CRISPR/Cas9 has been used to effectively modify the genome
of various species to inactivate genes or knock-in desired sequences (Wei et al., 2013). Lo et al.
(2013) demonstrated that CRISPR/Cas9 was highly effective at inducing precise indels or
mutations that are heritable in a diverse number of nematodes, including Pristionchus pacificus

24

and C. elegans which are diverged 300 million years ago. This system also requires exogenous
plasmids to be introduced into an organism without harm to the host. If a stable system is
developed to introduce plasmids designed for piggyBac transfection into B. malayi, it could be
adapted for targeted genome engineering with CRISPR/Cas9.
These studies could be applied to research into various drug targets. As previously
mentioned, the current drugs mostly target the larval stages or the Wolbachia and do not have
much of an effect on the adult stages. Several targets have been proposed, such as the nematode
molting pathways and the nervous system (Scott & Ghedin, 2009). Filarial parasite biology is
also of interest to human transplant research, due to the adult’s ability modulate the host immune
reaction and persist in individuals for years without being detected by any immune reaction
(Maizels & Yazdanbakhsh, 2003).
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